This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
ebola virus | 1510 |
ebov gp | 464 |
marburg virus | 258 |
virus infection | 257 |
virus disease | 252 |
hemorrhagic fever | 242 |
ebov infection | 237 |
virus glycoprotein | 174 |
nonhuman primates | 134 |
type i | 128 |
respiratory syndrome | 118 |
vesicular stomatitis | 113 |
dendritic cells | 110 |
ebola hemorrhagic | 107 |
sierra leone | 105 |
host cell | 99 |
stomatitis virus | 97 |
virus entry | 95 |
amino acid | 92 |
public health | 91 |
west africa | 88 |
cell surface | 88 |
antiviral activity | 85 |
democratic republic | 85 |
infected cells | 84 |
like particles | 83 |
immune responses | 83 |
plasma membrane | 81 |
viral replication | 80 |
rna viruses | 80 |
cell lines | 80 |
viral load | 79 |
syndrome coronavirus | 79 |
immune response | 78 |
target cells | 76 |
guinea pigs | 76 |
pseudotyped virus | 76 |
viral entry | 75 |
haemorrhagic fever | 75 |
cell entry | 74 |
acute respiratory | 73 |
marburg viruses | 72 |
zaire ebolavirus | 71 |
infectious diseases | 70 |
monoclonal antibodies | 68 |
neutralizing antibodies | 68 |
influenza virus | 68 |
middle east | 67 |
viral rna | 66 |
immunodeficiency virus | 66 |
severe acute | 65 |
neutralizing antibody | 63 |
filovirus infection | 61 |
virus vp | 60 |
evd patients | 59 |
cord uid | 58 |
doc id | 58 |
filovirus entry | 58 |
east respiratory | 57 |
fruit bats | 55 |
rhesus macaques | 55 |
human immunodeficiency | 54 |
west african | 54 |
rna polymerase | 53 |
binding site | 53 |
cell types | 52 |
previously described | 52 |
ebov vp | 52 |
membrane fusion | 52 |
viral infection | 52 |
i ifn | 52 |
marburg hemorrhagic | 52 |
matrix protein | 51 |
ebov entry | 51 |
fever virus | 51 |
cell culture | 50 |
virus replication | 49 |
mg kg | 48 |
cell fusion | 48 |
virus infections | 48 |
gp pseudotyped | 47 |
low ph | 46 |
room temperature | 46 |
endothelial cells | 46 |
ebola viruses | 46 |
clinical trials | 46 |
enveloped viruses | 45 |
gp cl | 45 |
cynomolgus macaques | 45 |
effector cells | 45 |
ebola outbreak | 45 |
world health | 45 |
health organization | 45 |
host cells | 43 |
approved drugs | 43 |
fruit bat | 42 |
infectious disease | 41 |
mg ml | 41 |
ebola haemorrhagic | 41 |
infected patients | 41 |
marv gp | 40 |
united states | 39 |
vp protein | 39 |
monoclonal antibody | 39 |
class i | 38 |
cell line | 38 |
viral proteins | 38 |
thermo fisher | 38 |
tetherin antagonism | 37 |
based vaccine | 37 |
western africa | 37 |
animal models | 36 |
evd outbreak | 36 |
small molecule | 35 |
positive cells | 35 |
mouse model | 35 |
virus particles | 35 |
cellular entry | 35 |
amino acids | 35 |
colored fruit | 35 |
live ebov | 34 |
african straw | 34 |
envelope glycoprotein | 34 |
fisher scientific | 34 |
described previously | 34 |
fusion protein | 34 |
avian influenza | 34 |
lethal ebola | 33 |
gene expression | 33 |
virus transmission | 33 |
phase i | 33 |
case fatality | 33 |
biosafety level | 32 |
ebov genome | 32 |
zaire ebola | 32 |
virus type | 32 |
pseudotyped hiv | 32 |
fecal samples | 32 |
health care | 32 |
fatality rate | 32 |
antibody titers | 32 |
glycan cap | 32 |
antibody responses | 32 |
viral envelope | 32 |
dendritic cell | 31 |
nipah virus | 31 |
genome sequences | 31 |
stranded rna | 31 |
ifn signaling | 31 |
viral fusion | 31 |
recombinant vesicular | 31 |
dependent rna | 31 |
clinical trial | 31 |
huh cells | 31 |
viral particles | 31 |
respiratory tract | 31 |
rna virus | 30 |
cell epitope | 30 |
viral genome | 30 |
lethal challenge | 30 |
highly pathogenic | 30 |
host immune | 30 |
purifying selection | 30 |
fusion loop | 30 |
immune system | 30 |
pfu ml | 30 |
equine antisera | 30 |
may also | 30 |
receptor binding | 30 |
i interferon | 29 |
innate immune | 29 |
virus gp | 29 |
viral infections | 29 |
blood samples | 29 |
life cycle | 29 |
hela cells | 29 |
ebov replication | 29 |
human infection | 29 |
npc domain | 29 |
pseudotyped viruses | 29 |
data sets | 29 |
sars coronavirus | 29 |
vaccine candidates | 28 |
hendra virus | 28 |
filovirus disease | 28 |
like particle | 28 |
gp i | 28 |
nonhuman primate | 28 |
ebov glycoprotein | 27 |
based vaccines | 27 |
bat cells | 27 |
viral protein | 27 |
guinea pig | 27 |
cell responses | 27 |
host range | 27 |
human primates | 26 |
cell epitopes | 26 |
virus challenge | 26 |
influenza viruses | 26 |
sexual transmission | 26 |
mucin domain | 26 |
reporter gene | 26 |
tnc mutations | 26 |
dna conjugates | 26 |
ebolavirus glycoprotein | 25 |
antibody response | 25 |
linked immunosorbent | 25 |
vaccine development | 25 |
glycoprotein gp | 25 |
human cases | 25 |
population coverage | 25 |
virus glycoproteins | 25 |
cholesterol transporter | 25 |
rna synthesis | 24 |
ebov infected | 24 |
animal model | 24 |
complete protection | 24 |
nucleic acid | 24 |
highly conserved | 24 |
vaccine design | 24 |
statistically significant | 24 |
negative control | 24 |
rhesus monkeys | 24 |
viral glycoprotein | 24 |
ebov outbreak | 24 |
incubation period | 24 |
proteolytic processing | 24 |
infected animals | 24 |
dengue virus | 24 |
ifn system | 23 |
fusion proteins | 23 |
rousettus aegyptiacus | 23 |
emerging pathogens | 23 |
viral spread | 23 |
electron microscopy | 23 |
vlp entry | 23 |
marv vp | 23 |
binding domain | 23 |
reverse transcription | 23 |
cov infection | 23 |
minigenome rna | 23 |
soluble non | 23 |
ng ml | 23 |
important role | 23 |
zaire ebov | 22 |
protein vp | 22 |
innate immunity | 22 |
virus outbreak | 22 |
human cells | 22 |
ebov infections | 22 |
ifitm proteins | 22 |
lethal ebov | 22 |
wide range | 22 |
ebola vaccine | 22 |
like domain | 22 |
peptide vaccine | 22 |
viral hemorrhagic | 22 |
high levels | 22 |
western blot | 22 |
previous studies | 22 |
protects nonhuman | 22 |
virus neutralization | 22 |
toremifene citrate | 21 |
performed using | 21 |
exporting country | 21 |
i ifns | 21 |
ebola viral | 21 |
african green | 21 |
mediated cell | 21 |
blood ebov | 21 |
trvlp infection | 21 |
human transmission | 21 |
vaccine protects | 21 |
lassa virus | 21 |
protein expression | 21 |
marv infection | 21 |
virus input | 21 |
present study | 21 |
well plates | 21 |
spectrum antiviral | 21 |
mediated fusion | 21 |
experimentally infected | 21 |
therapeutic agents | 21 |
flow cytometry | 21 |
entry requires | 21 |
human travel | 21 |
disease outbreaks | 21 |
immunosorbent assay | 21 |
prime boost | 20 |
zika virus | 20 |
drnpc domain | 20 |
entry mediated | 20 |
replication cycle | 20 |
heptad repeat | 20 |
tetherin expression | 20 |
cells via | 20 |
molecular dynamics | 20 |
fatality rates | 20 |
clinical signs | 20 |
time point | 20 |
yellow fever | 20 |
sequence alignment | 20 |
weight loss | 20 |
endoplasmic reticulum | 20 |
peripheral blood | 20 |
myeloid cells | 20 |
transporter niemann | 20 |
competing interests | 20 |
disease control | 20 |
time points | 20 |
risk factors | 20 |
protective efficacy | 20 |
cathepsin activity | 20 |
bovine serum | 20 |
per well | 20 |
creative commons | 20 |
evd survivors | 20 |
transmembrane domain | 20 |
small molecules | 20 |
directional changes | 19 |
immune evasion | 19 |
dependent manner | 19 |
transfected cells | 19 |
helix bundle | 19 |
late endosomes | 19 |
samples collected | 19 |
inflammatory responses | 19 |
cleavage site | 19 |
ebov mak | 19 |
proinflammatory cytokines | 19 |
encephalitis virus | 19 |
primary human | 19 |
emerging infectious | 19 |
molecule inhibitors | 19 |
based assay | 19 |
furin cleavage | 19 |
supplementary material | 19 |
life technologies | 19 |
cell viability | 19 |
emerging viral | 19 |
gp expression | 19 |
luciferase reporter | 19 |
days post | 19 |
adaptive immune | 19 |
family filoviridae | 19 |
specific antibodies | 19 |
plate reader | 19 |
crystal structure | 19 |
supportive care | 19 |
branch lengths | 18 |
infected mice | 18 |
human ebov | 18 |
host factors | 18 |
natural reservoir | 18 |
single dose | 18 |
postexposure protection | 18 |
plasmids encoding | 18 |
based assays | 18 |
passive transfer | 18 |
cytokine dysregulation | 18 |
results suggest | 18 |
commonly used | 18 |
tissue culture | 18 |
log tcid | 18 |
endosomal membrane | 18 |
necrosis factor | 18 |
type lectin | 18 |
viral membrane | 18 |
kcal mol | 18 |
viral pathogens | 18 |
tissue factor | 18 |
rna interference | 18 |
infection ebola | 18 |
vaccinia virus | 18 |
clinical features | 18 |
fda approved | 18 |
envelope glycoproteins | 18 |
three times | 18 |
like receptor | 18 |
immune activation | 18 |
ebov vlps | 18 |
protein kinase | 18 |
central africa | 18 |
south korea | 17 |
signaling pathways | 17 |
neutralisation assay | 17 |
gp subunit | 17 |
severe disease | 17 |
com scientificreports | 17 |
reverse genetics | 17 |
ebov challenge | 17 |
pseudotyped vsv | 17 |
nile virus | 17 |
adverse events | 17 |
rhesus macaque | 17 |
secondary structure | 17 |
significant difference | 17 |
cleaved gp | 17 |
structural proteins | 17 |
ebov activity | 17 |
positive selection | 17 |
ebov genomes | 17 |
human infections | 17 |
final concentration | 17 |
microfluidic cartridge | 17 |
gp furin | 17 |
cell lysates | 17 |
ri rna | 17 |
elevated levels | 17 |
virus vaccine | 17 |
plasma samples | 17 |
west nile | 17 |
mpxv infection | 17 |
human survivor | 17 |
conformational changes | 17 |
respiratory syncytial | 16 |
reservoir hosts | 16 |
exposure treatment | 16 |
ebola infection | 16 |
virus neutralisation | 16 |
data set | 16 |
lassa fever | 16 |
syncytial virus | 16 |
cell activation | 16 |
target cell | 16 |
type lectins | 16 |
gxxxg motif | 16 |
least one | 16 |
ebov neutralisation | 16 |
information regarding | 16 |
tumor necrosis | 16 |
hemorrhagic fevers | 16 |
reston virus | 16 |
fusion pore | 16 |
human macrophages | 16 |
ic values | 16 |
emerging viruses | 16 |
reston ebolavirus | 16 |
hspa motif | 16 |
family members | 16 |
ebov rna | 16 |
filovirus glycoproteins | 16 |
recombinant vsv | 16 |
viral loads | 16 |
cell cultures | 16 |
envelope protein | 16 |
lake victoria | 16 |
human ebola | 16 |
three areas | 16 |
kinase inhibitors | 16 |
mediated protection | 16 |
green monkey | 16 |
molecular mechanisms | 15 |
lymphoid tissues | 15 |
humoral immunity | 15 |
intravascular coagulation | 15 |
folate receptor | 15 |
nucleocapsid proteins | 15 |
march proteins | 15 |
gp gene | 15 |
rna editing | 15 |
antigen presentation | 15 |
restriction factor | 15 |
extracellular vesicles | 15 |
african outbreak | 15 |
ebov disease | 15 |
virus strains | 15 |
control group | 15 |
small animal | 15 |
lethal infection | 15 |
expression plasmid | 15 |
single particle | 15 |
equine encephalitis | 15 |
rna genome | 15 |
cell signaling | 15 |
substitution rates | 15 |
endothelial cell | 15 |
filoviridae family | 15 |
isg induction | 15 |
secondary antibody | 15 |
recent years | 15 |
authors declare | 15 |
binding affinity | 15 |
virus envelope | 15 |
plaque assay | 15 |
previously reported | 15 |
cells expressing | 15 |
bodily fluids | 15 |
neutralization assay | 15 |
african ebola | 15 |
ebolavirus infection | 15 |
cysteine proteases | 15 |
significantly higher | 15 |
filovirus infections | 15 |
fatal cases | 15 |
virus vaccines | 15 |
vero cells | 15 |
african countries | 15 |
neutralisation assays | 15 |
survival rate | 15 |
single amino | 15 |
legal trade | 15 |
lethal dose | 15 |
insect cells | 15 |
disease onset | 15 |
entry inhibitors | 15 |
spike protein | 15 |
ebola treatment | 14 |
surface protein | 14 |
vaccine vectors | 14 |
recombinant human | 14 |
length gp | 14 |
side effects | 14 |
fetal bovine | 14 |
ebola zaire | 14 |
valley fever | 14 |
inhibitors reveal | 14 |
ebov makona | 14 |
high degree | 14 |
specific antibody | 14 |
gp mrna | 14 |
rift valley | 14 |
goat anti | 14 |
transcriptional editing | 14 |
disease outbreak | 14 |
ebov negative | 14 |
great ape | 14 |
saharan africa | 14 |
glycoprotein bound | 14 |
vectors expressing | 14 |
internal branches | 14 |
jui government | 14 |
ebola epidemic | 14 |
protective immunity | 14 |
copies ml | 14 |
filovirus gp | 14 |
sudan ebola | 14 |
infected nhps | 14 |
even though | 14 |
ebov igg | 14 |
animal studies | 14 |
reveal niemann | 14 |
virus detection | 14 |
serum panel | 14 |
npc binding | 14 |
may provide | 14 |
virus ebola | 14 |
mhc class | 14 |
clinical manifestations | 14 |
generation sequencing | 14 |
dna vaccine | 14 |
min ph | 14 |
recent studies | 14 |
fused scfv | 14 |
tcid ml | 14 |
vp proteins | 14 |
recent outbreak | 14 |
forming units | 14 |
infection control | 14 |
gp contains | 14 |
buffered saline | 14 |
body fluids | 14 |
control antigen | 13 |
i interferons | 13 |
protective equipment | 13 |
virus isolation | 13 |
lymph nodes | 13 |
ng pcaggs | 13 |
host responses | 13 |
substitution models | 13 |
pathogenic avian | 13 |
new world | 13 |
acid residues | 13 |
sequence analysis | 13 |
experimental infection | 13 |
three different | 13 |
internal fusion | 13 |
different cell | 13 |
victoria marburgvirus | 13 |
swab samples | 13 |
wild type | 13 |
whole blood | 13 |
mammalian cells | 13 |
rna secondary | 13 |
multiorgan failure | 13 |
directional change | 13 |
human disease | 13 |
expressing ebola | 13 |
saudi arabia | 13 |
entry receptor | 13 |
evd survivor | 13 |
causative agent | 13 |
theraflex mb | 13 |
inhibit ebov | 13 |
human tetherin | 13 |
taken together | 13 |
determine whether | 13 |
image analysis | 13 |
currently available | 13 |
endosomal proteolysis | 13 |
culture medium | 13 |
neutralizing activity | 13 |
disseminated intravascular | 13 |
inhibit ebola | 13 |
gp proteins | 13 |
multiple sequence | 13 |
congo basin | 13 |
government hospital | 13 |
lymphocyte apoptosis | 13 |
experimental ebola | 13 |
secondary structures | 13 |
human evd | 13 |
increased risk | 13 |
cov outbreak | 13 |
sense rna | 13 |
transcription factor | 13 |
including ebov | 13 |
expression vector | 13 |
response curves | 13 |
convalescent plasma | 13 |
cellular responses | 13 |
without vlps | 13 |
clinical management | 13 |
higher levels | 13 |
epithelial cells | 13 |
cell immunoglobulin | 13 |
ebov virus | 13 |
humoral immune | 13 |
great apes | 13 |
host proteins | 13 |
infected individuals | 12 |
genbank accession | 12 |
cleaved ebov | 12 |
nucleoside analogues | 12 |
late endosomal | 12 |
dromedary camels | 12 |
particle release | 12 |
current study | 12 |
raw product | 12 |
three independent | 12 |
ph pulse | 12 |
web server | 12 |
virus shedding | 12 |
abdominal pain | 12 |
ah conditions | 12 |
mers coronavirus | 12 |
mortality rates | 12 |
vaccine expressing | 12 |
viral dissemination | 12 |
positive control | 12 |
human dendritic | 12 |
serial dilutions | 12 |
detected using | 12 |
exposure protection | 12 |
large number | 12 |
virus nucleoprotein | 12 |
egyptian fruit | 12 |
cell membrane | 12 |
polymerase chain | 12 |
branch length | 12 |
authentic ebov | 12 |
intracellular receptor | 12 |
healthy adults | 12 |
thermofisher scientific | 12 |
gfp minigenome | 12 |
dna sequences | 12 |
may result | 12 |
nh cl | 12 |
hong kong | 12 |
measured using | 12 |
high viral | 12 |
confirmed cases | 12 |
ebolavirus vp | 12 |
dna vaccines | 12 |
years ago | 12 |
eu mss | 12 |
chain reaction | 12 |
ebola vaccines | 12 |
surface hspa | 12 |
mva ebov | 12 |
plasmacytoid dendritic | 12 |
data indicate | 12 |
commons license | 12 |
common marmoset | 12 |
simian immunodeficiency | 12 |
conformational change | 12 |
cell immunity | 12 |
viral glycoproteins | 12 |
primate models | 12 |
pick type | 12 |
drug administration | 12 |
also showed | 12 |
endosomal cathepsins | 12 |
low levels | 12 |
post infection | 12 |
clomiphene citrate | 12 |
mortality rate | 12 |
vsv pseudotypes | 12 |
drug target | 12 |
personal protective | 12 |
negative serum | 12 |
nucleic acids | 12 |
controlled trial | 12 |
genome replication | 12 |
graphpad prism | 12 |
evd outbreaks | 12 |
venezuelan equine | 12 |
virus nucleocapsid | 12 |
virus titers | 12 |
log reduction | 12 |
i clinical | 12 |
national institutes | 12 |
bearing ebov | 12 |
central african | 12 |
fatal disease | 12 |
cell cytoplasm | 12 |
disease ebola | 12 |
ebov vaccine | 12 |
terminal heptad | 12 |
thermolysin treatment | 11 |
quantified using | 11 |
recombinant adenovirus | 11 |
post transfection | 11 |
entry driven | 11 |
sodium dodecyl | 11 |
throughput screening | 11 |
dependent enhancement | 11 |
ebov strains | 11 |
zaire strain | 11 |
adapted ebov | 11 |
clinical data | 11 |
regulatory factor | 11 |
one study | 11 |
gel electrophoresis | 11 |
mononuclear cells | 11 |
disease progression | 11 |
virus enters | 11 |
coagulation abnormalities | 11 |
surviving patients | 11 |
phylogenetic analysis | 11 |
broad range | 11 |
protein interactions | 11 |
ebov lifecycle | 11 |
likely due | 11 |
day post | 11 |
cohort study | 11 |
healthcare workers | 11 |
enveloped virus | 11 |
eidolon helvum | 11 |
patients infected | 11 |
different ebov | 11 |
decreasing trend | 11 |
pseudotypes bearing | 11 |
within days | 11 |
animal species | 11 |
nhp model | 11 |
transferrin receptor | 11 |
host response | 11 |
ebov np | 11 |
cell layer | 11 |
binding protein | 11 |
disease surveillance | 11 |
late endosome | 11 |
polymerase cofactor | 11 |
rate variation | 11 |
presenting cells | 11 |
vaccinated mice | 11 |
hydrogen bond | 11 |
pbs group | 11 |
day postexposure | 11 |
nucleoside analogs | 11 |
convalescent patients | 11 |
neutral ph | 11 |
strand rna | 11 |
protein sequences | 11 |
antiviral activities | 11 |
therapeutic antisera | 11 |
postexposure prophylaxis | 11 |
human antibody | 11 |
using pseudotyped | 11 |
electron tomography | 11 |
mb light | 11 |
iav ha | 11 |
introduction event | 11 |
ebov fusion | 11 |
preliminary report | 11 |
proposed epitope | 11 |
virus specific | 11 |
existing immunity | 11 |
based ebola | 11 |
bat species | 11 |
virus genomes | 11 |
sudan virus | 11 |
cell tropism | 11 |
advanced ebola | 11 |
infectious virus | 11 |
specific igg | 11 |
expression levels | 11 |
tnc substitutions | 11 |
ebolavirus species | 11 |
ebov particles | 11 |
influenza vaccine | 11 |
respiratory disease | 11 |
associated proteins | 11 |
fusion events | 11 |
substitution model | 11 |
encoding ebov | 11 |
first time | 11 |
direct contact | 11 |
virion glycoproteins | 11 |
error bars | 11 |
imported case | 11 |
national institute | 11 |
correlation coefficients | 11 |
nonendemic countries | 11 |
inflammatory cytokines | 11 |
successful treatment | 11 |
heavily glycosylated | 11 |
fusion pores | 11 |
np i | 11 |
tetherin counteraction | 11 |
inflammatory response | 11 |
two different | 11 |
laboratory studies | 11 |
adaptive immunity | 11 |
soluble gp | 11 |
viral life | 11 |
lectins dc | 10 |
serum panels | 10 |
inhibition assay | 10 |
igg antibody | 10 |
host endosomal | 10 |
recent study | 10 |
also used | 10 |
mev rpv | 10 |
viral genomes | 10 |
mouse igg | 10 |
confirmed evd | 10 |
binding free | 10 |
novel coronavirus | 10 |
kinome analysis | 10 |
peptide arrays | 10 |
infection resulted | 10 |
nucleotide substitution | 10 |
different viruses | 10 |
strains isolated | 10 |
acute infection | 10 |
clinical presentation | 10 |
high mortality | 10 |
cytoplasmic tail | 10 |
software package | 10 |
independent experiments | 10 |
molecular basis | 10 |
expression vectors | 10 |
functional analysis | 10 |
egyptian rousettes | 10 |
regression analysis | 10 |
infected cynomolgus | 10 |
marv entry | 10 |
open reading | 10 |
treated animals | 10 |
via macropinocytosis | 10 |
total antibody | 10 |
also found | 10 |
statistical analysis | 10 |
specific cd | 10 |
cellular immunity | 10 |
ebov epidemic | 10 |
cleaved form | 10 |
contact tracing | 10 |
viral transcription | 10 |
rpv pprv | 10 |
sigma adjuvant | 10 |
medium containing | 10 |
tetherin antagonist | 10 |
vaccine platforms | 10 |
ebov spread | 10 |
luciferase signal | 10 |
genome sequencing | 10 |
inhibitory activity | 10 |
sustained targets | 10 |
cellular membranes | 10 |
initial viral | 10 |
cell response | 10 |
fused scfvs | 10 |
potential therapeutic | 10 |
leukemia virus | 10 |
well plate | 10 |
inhibit filovirus | 10 |
estrogen receptor | 10 |
ebola outbreaks | 10 |
acid residue | 10 |
open access | 10 |
repeat region | 10 |
cell type | 10 |
clinical observations | 10 |
receptor niemann | 10 |
reading frame | 10 |
genomic surveillance | 10 |
ctl vaccine | 10 |
way anova | 10 |
fusion induced | 10 |
bundibugyo ebolavirus | 10 |
human papillomavirus | 10 |
confocal microscopy | 10 |
evd cases | 10 |
epitope prediction | 10 |
alpha beta | 10 |
makona variant | 10 |
vp may | 10 |
culture supernatant | 10 |
virus fusion | 10 |
global health | 10 |
cell death | 10 |
dce sum | 10 |
platelet concentrates | 10 |
patients treated | 10 |
fever viruses | 10 |
antiviral effects | 10 |
therapeutic targets | 10 |
wt mice | 10 |
interferon response | 10 |
reproductive tract | 10 |
free energy | 10 |
cellular membrane | 10 |
vaccine efficacy | 10 |
monkey kidney | 10 |
infected cell | 10 |
reading frames | 10 |
acidic ph | 10 |
structural basis | 10 |
particles produced | 10 |
ebov isolate | 10 |
eu ms | 10 |
genomic rna | 10 |
treatment group | 10 |
decay rates | 10 |
humoral responses | 10 |
tyrosine kinase | 10 |
antiviral response | 10 |
expressing ebov | 10 |
also shown | 10 |
significant differences | 10 |
common features | 10 |
gp sequences | 10 |
standard error | 10 |
cationic amphiphiles | 10 |
direct effect | 10 |
viral diseases | 10 |
serum samples | 10 |
statistical significance | 10 |
virus density | 10 |
endemic areas | 10 |
cell receptor | 10 |
primate model | 10 |
cathepsin cleavage | 10 |
antibodies directed | 10 |
virus persistence | 10 |
substitutions site | 10 |
expressing cells | 10 |
ebov proteins | 10 |
endosomal membranes | 10 |
host protein | 10 |
functional characterization | 9 |
plasma concentrations | 9 |
activated protein | 9 |
united kingdom | 9 |
proteolytic cleavage | 9 |
respiratory distress | 9 |
horseradish peroxidase | 9 |
ebov minigenome | 9 |
shock protein | 9 |
stably expressing | 9 |
endocytic pathway | 9 |
average number | 9 |
converting enzyme | 9 |
human fatal | 9 |
early stages | 9 |
aberrant innate | 9 |
asymptomatic ebola | 9 |
first months | 9 |
virus particle | 9 |
virus prevalence | 9 |
mediate cellular | 9 |
flag antibody | 9 |
fibrin deposition | 9 |
shed gp | 9 |
blood transfusions | 9 |
ebov trailer | 9 |
mm tris | 9 |
human macrophage | 9 |
rapid diagnosis | 9 |
boost vaccination | 9 |
whether ebov | 9 |
wild great | 9 |
significantly reduced | 9 |
virus matrix | 9 |
virus origin | 9 |
high dose | 9 |
european union | 9 |
total number | 9 |
geometric mean | 9 |
surveillance elucidates | 9 |
dynamics simulation | 9 |
human monocytes | 9 |
ring vaccination | 9 |
distinct mechanisms | 9 |
factor viia | 9 |
ebola patients | 9 |
rna binding | 9 |
ebola glycoprotein | 9 |
natural host | 9 |
cells treated | 9 |
macaque model | 9 |
chimpanzee adenovirus | 9 |
pandemic influenza | 9 |
ebov viral | 9 |
ifn induction | 9 |
disease severity | 9 |
situation report | 9 |
big data | 9 |
mediated immune | 9 |
selective estrogen | 9 |
supplementary data | 9 |
recombinant nematode | 9 |
fusion mediated | 9 |
passive immunization | 9 |
complex formation | 9 |
endosomal acidification | 9 |
lineage dual | 9 |
discovery studio | 9 |
massive lymphocyte | 9 |
ebov vlp | 9 |
expression plasmids | 9 |
ebola response | 9 |
derived dendritic | 9 |
symptom onset | 9 |
viral titers | 9 |
penicillin streptomycin | 9 |
membrane protein | 9 |
closely related | 9 |
within endosomes | 9 |
md simulations | 9 |
filovirus family | 9 |
aegyptiacus bats | 9 |
may play | 9 |
channel blocker | 9 |
ad vaccine | 9 |
virus proteins | 9 |
plasmid encoding | 9 |
gp gp | 9 |
viral vectors | 9 |
elisa plates | 9 |
pbs containing | 9 |
data analysis | 9 |
mediated endocytosis | 9 |
blood mononuclear | 9 |
mayinga strain | 9 |
therapeutic efficacy | 9 |
important factor | 9 |
virus infectivity | 9 |
chikungunya virus | 9 |
inhibitory concentration | 9 |
filoviral entry | 9 |
filoviral hemorrhagic | 9 |
affected countries | 9 |
using recombinant | 9 |
plasma levels | 9 |
international scientific | 9 |
molecular weight | 9 |
infectious agents | 9 |
substitution rate | 9 |
ebov trvlp | 9 |
using different | 9 |
takes place | 9 |
commercially available | 9 |
modified vaccinia | 9 |
current outbreak | 9 |
nucleocapsid protein | 9 |
proinflammatory cytokine | 9 |
recombinant ebov | 9 |
transfection reagent | 9 |
i fusion | 9 |
morpholino oligomers | 9 |
south africa | 9 |
external solution | 9 |
elucidates ebola | 9 |
disease epidemiology | 9 |
mechanical ventilation | 9 |
antiviral immunity | 9 |
early stage | 9 |
vsv vectors | 9 |
van der | 9 |
cellular proteins | 9 |
safety profile | 9 |
calcium channel | 9 |
three subtypes | 9 |
total rna | 9 |
fold higher | 9 |
binding pocket | 9 |
cellular receptors | 9 |
mediated restriction | 9 |
cleave ebov | 9 |
endosomal proteases | 9 |
cells infected | 9 |
weeks post | 9 |
common feature | 9 |
metagenomic sequencing | 9 |
deficient mice | 9 |
binding sites | 9 |
virus spread | 9 |
dependent protein | 9 |
total gp | 9 |
receptor modulators | 9 |
der waals | 9 |
mpxv infections | 9 |
critical role | 9 |
results indicate | 9 |
turned negative | 9 |
ct values | 9 |
virus genome | 9 |
post disease | 9 |
gp processing | 9 |
like structures | 9 |
poorly understood | 9 |
viral disease | 9 |
attenuated recombinant | 9 |
passive microfluidic | 9 |
emerging infections | 9 |
neutralizing monoclonal | 9 |
sucrose cushion | 9 |
fever ebola | 9 |
phage display | 9 |
dodecyl sulfate | 9 |
human antibodies | 9 |
theraflex uv | 9 |
virus load | 9 |
live virus | 9 |
vascular permeability | 9 |
care workers | 9 |
may reflect | 8 |
virus polymerase | 8 |
length ebov | 8 |
tested positive | 8 |
antibody kz | 8 |
drug targets | 8 |
i studies | 8 |
virus rna | 8 |
drug resistance | 8 |
dependent inhibition | 8 |
replication promoter | 8 |
two weeks | 8 |
needle stick | 8 |
npc orthologs | 8 |
ec values | 8 |
functional antibody | 8 |
described elsewhere | 8 |
ebov may | 8 |
data suggest | 8 |
lesser extent | 8 |
human march | 8 |
postexposure antibody | 8 |
antibody immobilization | 8 |
protein sequence | 8 |
antigenic protein | 8 |
marburg haemorrhagic | 8 |
regulatory approval | 8 |
health response | 8 |
acid changes | 8 |
commons attribution | 8 |
multiple cell | 8 |
dynamics simulations | 8 |
crystal structures | 8 |
receptor alpha | 8 |
ready form | 8 |
molecular docking | 8 |
drug discovery | 8 |
vivo studies | 8 |
bars indicate | 8 |
outbreak setting | 8 |
suspected cases | 8 |
greatly reduced | 8 |
ribonucleoprotein complex | 8 |
content imaging | 8 |
readily available | 8 |
supplementary table | 8 |
ill patients | 8 |
filoviral gp | 8 |
cell lysate | 8 |
determined using | 8 |
severe covid | 8 |
log day | 8 |
filovirus cell | 8 |
anticoagulant protein | 8 |
neutralizing human | 8 |
endo lysosomal | 8 |
selective pressure | 8 |
therapeutic approaches | 8 |
igy antibodies | 8 |
one outbreak | 8 |
monocytes macrophages | 8 |
phase iii | 8 |
expression system | 8 |
acute phase | 8 |
recovery process | 8 |
viruses ebola | 8 |
dcs may | 8 |
eahy cells | 8 |
africa ebola | 8 |
clinical studies | 8 |
findings suggest | 8 |
gp protein | 8 |
bat populations | 8 |
treatment center | 8 |
ebov antibody | 8 |
experimental inoculation | 8 |
fluorescent protein | 8 |
cells transfected | 8 |
sudv gp | 8 |
bat npc | 8 |
also observed | 8 |
neutralising antibodies | 8 |
graphpad software | 8 |
viral data | 8 |
fps sum | 8 |
host membrane | 8 |
renilla luciferase | 8 |
mouse models | 8 |
cell system | 8 |
pathogenic viruses | 8 |
murine leukemia | 8 |
western african | 8 |
heat shock | 8 |
cellular targets | 8 |
culture supernatants | 8 |
african evd | 8 |
ebov species | 8 |
previous work | 8 |
gp cleavage | 8 |
technical committee | 8 |
human monoclonal | 8 |
protect nonhuman | 8 |
viral haemorrhagic | 8 |
different species | 8 |
growth factor | 8 |
genome sequence | 8 |
sequence data | 8 |
mechanisms underlying | 8 |
kindly provided | 8 |
nns rna | 8 |
live animal | 8 |
human igg | 8 |
nitric oxide | 8 |
antibody titres | 8 |
similar results | 8 |
virus surface | 8 |
will require | 8 |
also demonstrated | 8 |
type calcium | 8 |
previous study | 8 |
molecular events | 8 |
fatal outcome | 8 |
chain termination | 8 |
acid sequences | 8 |
congo hemorrhagic | 8 |
molecular dating | 8 |
antibody prophylaxis | 8 |
endosomal lysosomal | 8 |
gene inhibition | 8 |
gp alone | 8 |
dimensional structure | 8 |
provide protection | 8 |
polyacrylamide gel | 8 |
us department | 8 |
clinical presentations | 8 |
vaccine candidate | 8 |
fatal zaire | 8 |
given ip | 8 |
normal distribution | 8 |
one year | 8 |
bats may | 8 |
full text | 8 |
nematode anticoagulant | 8 |
gb virus | 8 |
infected marmosets | 8 |
green monkeys | 8 |
endosomal cysteine | 8 |
ge healthcare | 8 |
cos cells | 8 |
reduced ebov | 8 |
medical countermeasures | 8 |
animals infected | 8 |
mem medium | 8 |
inhibitory effect | 8 |
highly immunogenic | 8 |
single nucleotide | 8 |
increasing amounts | 8 |
green fluorescent | 8 |
supplemental table | 8 |
molecular mechanism | 8 |
disease virus | 8 |
block ebov | 8 |
common among | 8 |
pregnant women | 8 |
clinical symptoms | 8 |
seven genes | 8 |
least two | 8 |
iris chip | 8 |
lymph node | 8 |
kinome peptide | 8 |
ebolavirus disease | 8 |
also detected | 8 |
higher doses | 8 |
ebov transmission | 8 |
forward projections | 8 |
viia tissue | 8 |
data presented | 8 |
north america | 8 |
endosomal receptor | 8 |
npc gene | 8 |
provides protection | 8 |
nucleoside analogue | 8 |
lassa viruses | 8 |
distress syndrome | 8 |
cells using | 8 |
cellular cholesterol | 8 |
another important | 8 |
viral antigens | 8 |
monkeypox virus | 8 |
human populations | 8 |
antibody prevalence | 8 |
gp fusion | 8 |
interferon signaling | 8 |
interferon regulatory | 8 |
cells stably | 8 |
high sensitivity | 8 |
firefly luciferase | 8 |
genetically diverse | 8 |
acid amplification | 8 |
human asymptomatic | 8 |
viral gp | 8 |
measles virus | 8 |
mouse anti | 8 |
evidence suggests | 8 |
previous reports | 8 |
human population | 7 |
antigen capture | 7 |
passive immunotherapy | 7 |
borne viruses | 7 |
hiv gag | 7 |
positive patients | 7 |
ammonium sulfate | 7 |
cho cells | 7 |
clinically approved | 7 |
mutation rate | 7 |
lethal disease | 7 |
seasonal pulses | 7 |
potent neutralizing | 7 |
fold serial | 7 |
respiratory symptoms | 7 |
response team | 7 |
environmental conditions | 7 |
gp residues | 7 |
remains neutral | 7 |
directly immobilized | 7 |
igg responses | 7 |
via siglec | 7 |
two groups | 7 |
current epidemic | 7 |
respiratory failure | 7 |
protein gp | 7 |
different strategies | 7 |
calcium channels | 7 |
virus nonstructural | 7 |
first immunization | 7 |
mutant lxxxl | 7 |
np protein | 7 |
surface accessibility | 7 |
host species | 7 |
point mutations | 7 |
recombinant vp | 7 |
marburg agent | 7 |
another study | 7 |
vp interaction | 7 |
scfv format | 7 |
vsv particles | 7 |
short stretches | 7 |
cell binding | 7 |
stomatitis viruses | 7 |
sialic acid | 7 |
clinical illness | 7 |
sequencing data | 7 |
severe sepsis | 7 |
body weight | 7 |
hospitalized patients | 7 |
neutralization assays | 7 |
proprotein convertase | 7 |
patient viral | 7 |
ebov infects | 7 |
small interfering | 7 |
test whether | 7 |
quality control | 7 |
protective effect | 7 |
recombinant protein | 7 |
important step | 7 |
outbreak response | 7 |
igg ebov | 7 |
virus binding | 7 |
enters host | 7 |
pcr primers | 7 |
gilead sciences | 7 |
beta turn | 7 |
also inhibited | 7 |
tyro family | 7 |
cellular immune | 7 |
common directional | 7 |
oral swab | 7 |
control measures | 7 |
ongoing outbreak | 7 |
reactive oxygen | 7 |
twice daily | 7 |
dye spread | 7 |
conserved region | 7 |
mediated immunity | 7 |
recently shown | 7 |
secondary lymphoid | 7 |
fei company | 7 |
jurisdictional claims | 7 |
analyses showed | 7 |
word count | 7 |
infectious dose | 7 |
thank dr | 7 |
coronavirus infection | 7 |
directed mutagenesis | 7 |
antiviral host | 7 |
mm nacl | 7 |
transmission events | 7 |
silico docking | 7 |
basin mpxv | 7 |
binding energy | 7 |
inhibitors targeting | 7 |
mice vaccinated | 7 |
peptide binding | 7 |
respiratory viruses | 7 |
rabies virus | 7 |
vp binding | 7 |
kda gp | 7 |
flow cartridge | 7 |
aids reagent | 7 |
past outbreaks | 7 |
supplementary file | 7 |
inner leaflet | 7 |
higher ah | 7 |
features pharmacophore | 7 |
human patients | 7 |
interferon responses | 7 |
standard deviations | 7 |
human activated | 7 |
co incubator | 7 |
viral mutation | 7 |
golgi apparatus | 7 |
detection limit | 7 |
coding regions | 7 |
standard deviation | 7 |
died within | 7 |
assay using | 7 |
cytopathic effect | 7 |
terminal domain | 7 |
infect cells | 7 |
treatment regimen | 7 |
vsv spread | 7 |
study demonstrated | 7 |
mice treated | 7 |
current ebola | 7 |
recombinant vaccine | 7 |
acid change | 7 |
phase trial | 7 |
entry inhibitor | 7 |
positive serum | 7 |
clinical research | 7 |
infection results | 7 |
counteract tetherin | 7 |
case scenario | 7 |
specific activity | 7 |
previously shown | 7 |
forest virus | 7 |
using lipofectamine | 7 |
receiver operating | 7 |
fatal human | 7 |
np antibodies | 7 |
published maps | 7 |
go soluble | 7 |
sign mediate | 7 |
studies using | 7 |
dpi survived | 7 |
ocular fluid | 7 |
antibody levels | 7 |
helvum npc | 7 |
transmission dynamics | 7 |
may occur | 7 |
per milliliter | 7 |
fatal evd | 7 |
kj mol | 7 |
virus life | 7 |
rabbit sera | 7 |
purification process | 7 |
cd cells | 7 |
severe ebola | 7 |
much lower | 7 |
cynomolgus monkeys | 7 |
clinical development | 7 |
virus circulation | 7 |
active metabolite | 7 |
lipid bilayer | 7 |
therapeutic strategies | 7 |
human influenza | 7 |
lower respiratory | 7 |
human cell | 7 |
fresh medium | 7 |
dose vaccination | 7 |
dependent entry | 7 |
scoring function | 7 |
molecular biology | 7 |
serological assays | 7 |
polymerase complex | 7 |
prophylaxis protects | 7 |
bombali virus | 7 |
viruses using | 7 |
broad antiviral | 7 |
viper npc | 7 |
filoviral infection | 7 |
current knowledge | 7 |
fps es | 7 |
persistent infection | 7 |
fusion peptide | 7 |
macaques infected | 7 |
metabolite deaq | 7 |
visualized using | 7 |
sl reference | 7 |
reduced fusion | 7 |
hsnpc domain | 7 |
ebolavirus antibodies | 7 |
increased vascular | 7 |
intracellular compartments | 7 |
ligand pharmacophores | 7 |
two reading | 7 |
five different | 7 |
secondary cases | 7 |
nature remains | 7 |
ifn response | 7 |
membrane proteins | 7 |
three viral | 7 |
vlp release | 7 |
disease patients | 7 |
use authorization | 7 |
entry via | 7 |
infectious ebov | 7 |
fold dilutions | 7 |
infection may | 7 |
absolute humidity | 7 |
viral shedding | 7 |
results demonstrate | 7 |
antiviral strategies | 7 |
vectored vaccine | 7 |
viruses doi | 7 |
filovirus vaccine | 7 |
callithrix jacchus | 7 |
diverse marburg | 7 |
inhibit viral | 7 |
ifn antagonism | 7 |
proinflammatory responses | 7 |
vp scfvs | 7 |
different strains | 7 |
series changes | 7 |
i binding | 7 |
post onset | 7 |
nucleoside analog | 7 |
based vectors | 7 |
zoonotic rna | 7 |
viral antigen | 7 |
infected nonhuman | 7 |
antibody cocktail | 7 |
chronic diseases | 7 |
zoonotic viruses | 7 |
molecular evidence | 7 |
institutional affiliations | 7 |
signal intensity | 7 |
study team | 7 |
past years | 7 |
factor tetherin | 7 |
human serum | 7 |
previous outbreaks | 7 |
docking simulation | 7 |
marv replication | 7 |
permissive cells | 7 |
ifn responses | 7 |
investigate whether | 7 |
blocks ebov | 7 |
several different | 7 |
ebov using | 7 |
vaccine platform | 7 |
intensive care | 7 |
gold standard | 7 |
nhp models | 7 |
wild animal | 7 |
antiviral responses | 7 |
will discuss | 7 |
methylene blue | 7 |
viral clearance | 7 |
serological survey | 7 |
gp subunits | 7 |
virus growth | 7 |
vp forms | 7 |
acid sequence | 7 |
based substitution | 7 |
spillover events | 7 |
ebov outbreaks | 7 |
surface gp | 7 |
deficient cell | 7 |
ebola vp | 7 |
expressing phage | 7 |
control mice | 7 |
recombinant inhibitor | 7 |
molecule inhibitor | 7 |
direct antiviral | 7 |
conservancy analysis | 7 |
accession number | 7 |
african mpxv | 7 |
igg antibodies | 7 |
fatal outcomes | 7 |
specific monoclonal | 7 |
ebola situation | 7 |
travel history | 7 |
loading dose | 7 |
genetic material | 7 |
transmission chains | 7 |
negative regulatory | 7 |
soluble mediators | 7 |
barrier function | 7 |
world arenavirus | 7 |
restriction sites | 7 |
reagent program | 7 |
sense single | 7 |
candidate vaccines | 7 |
humans infected | 7 |
calculated using | 7 |
septic shock | 7 |
lung pathogenesis | 7 |
vaccines based | 7 |
significantly different | 7 |
erk mapk | 7 |
pediatric patients | 7 |
antiviral agents | 7 |
induced transmembrane | 7 |
ebov patients | 7 |
polymerase inhibitor | 7 |
experimental testing | 7 |
dna spots | 7 |
clustered together | 7 |
virus genomic | 7 |
viral nucleoprotein | 7 |
gp structure | 7 |
dsrna binding | 7 |
transmembrane proteins | 7 |
rnp complex | 7 |
cells well | 7 |
egyptian rousette | 7 |
nucleocapsid formation | 7 |
frequently used | 7 |
surface proteins | 7 |
drug screen | 7 |
springer nature | 7 |
specific binding | 7 |
severe hemorrhagic | 7 |
coiled coil | 7 |
retinoic acid | 6 |
force field | 6 |
health measures | 6 |
hypsignathus monstrosus | 6 |
vectors encoding | 6 |
may affect | 6 |
luciferase assay | 6 |
tai forest | 6 |
interferon antagonism | 6 |
clinical samples | 6 |
jsrv env | 6 |
long oligonucleotides | 6 |
mm mgcl | 6 |
efficient entry | 6 |
induced cytolysis | 6 |
bats coincide | 6 |
evolutionary dynamics | 6 |
genome length | 6 |
nuclear import | 6 |
effectively neutralized | 6 |
either ebov | 6 |
ebov attachment | 6 |
mediated tetherin | 6 |
cathepsin inhibitors | 6 |
three human | 6 |
phase ii | 6 |
virus antigen | 6 |
natural hosts | 6 |
available data | 6 |
also known | 6 |
glycoprotein sgp | 6 |
calcium phosphate | 6 |
ebov nucleocapsid | 6 |
mrna stability | 6 |
chest pain | 6 |
viral receptor | 6 |
vlp treatment | 6 |
small soluble | 6 |
mutations within | 6 |
pcr products | 6 |
adjuvanted ebov | 6 |
macaque models | 6 |
wt gp | 6 |
fluorescent assay | 6 |
antibody produced | 6 |
cell pairs | 6 |
infectious pathogens | 6 |
adjuvanted microsphere | 6 |
bat genomes | 6 |
human embryonic | 6 |
male reproductive | 6 |
expressing hafl | 6 |
much higher | 6 |
isothermal amplification | 6 |
culture media | 6 |
cholesterol clearance | 6 |
sequence similarity | 6 |
data collected | 6 |
weeks later | 6 |
adult patients | 6 |
ebov detection | 6 |
intramuscular injection | 6 |
dual model | 6 |
median age | 6 |
virus assays | 6 |
solved structure | 6 |
gp binding | 6 |
viral elements | 6 |
stimulated genes | 6 |
fresh growth | 6 |
libdock scores | 6 |
th century | 6 |
patients may | 6 |
expressing marv | 6 |
one introduction | 6 |
viral genes | 6 |
randomized controlled | 6 |
junin virus | 6 |
decay rate | 6 |
histocompatibility complex | 6 |
mice without | 6 |
infectious ebola | 6 |
high level | 6 |
homogeneous assay | 6 |
tetherin inhibits | 6 |
natural history | 6 |
plasmodium falciparum | 6 |
hla molecule | 6 |
gp antibodies | 6 |
expressing phages | 6 |
antibody binding | 6 |
epitope identification | 6 |
may contribute | 6 |
hydrophobic residues | 6 |
live attenuated | 6 |
natural human | 6 |
combination therapy | 6 |
human outbreaks | 6 |
march inhibits | 6 |
adenovirus serotype | 6 |
prolongs survival | 6 |
plos one | 6 |
protect mice | 6 |
liver enzymes | 6 |
small glycoprotein | 6 |
africa outbreak | 6 |
data obtained | 6 |
animal origin | 6 |
two distinct | 6 |
direct exposure | 6 |
pore formation | 6 |
care worker | 6 |
phosphorodiamidate morpholino | 6 |
macropinocytic pathway | 6 |
human pathogens | 6 |
glycosylated mucin | 6 |
virus strain | 6 |
therapy prolongs | 6 |
multiple cationic | 6 |
positive results | 6 |
syndrome virus | 6 |
nonstructural small | 6 |
promising candidates | 6 |
nonporous surfaces | 6 |
march expression | 6 |
virus families | 6 |
hiv gp | 6 |
virus densities | 6 |
vaccine effectiveness | 6 |
evolutionary rate | 6 |
induce fusion | 6 |
sequence changes | 6 |
cancer therapy | 6 |
kind gift | 6 |
laboratory diagnosis | 6 |
covalent modifications | 6 |
tested negative | 6 |
human clinical | 6 |
virus vector | 6 |
experimental infections | 6 |
mediated entry | 6 |
chemokine expression | 6 |
modulators inhibit | 6 |
fps vdw | 6 |
coomassie blue | 6 |
viral persistence | 6 |
new insights | 6 |
primary antibody | 6 |
ebov antibodies | 6 |
viral genomic | 6 |
received vlps | 6 |
available therapeutic | 6 |
highly divergent | 6 |
virus sample | 6 |
causes lethal | 6 |
treatment options | 6 |
infected humans | 6 |
close contact | 6 |
ebov persistence | 6 |
ebov survivors | 6 |
structural integrity | 6 |
conjugated secondary | 6 |
obtained using | 6 |
ravv ravn | 6 |
nk cells | 6 |
transmembrane protein | 6 |
bacterial translocation | 6 |
major histocompatibility | 6 |
minigenome assay | 6 |
ebolavirus challenge | 6 |
peer review | 6 |
type virus | 6 |
potential threat | 6 |
similar dose | 6 |
genomic replication | 6 |
virus makona | 6 |
precursor gp | 6 |
first reported | 6 |
surface glycoprotein | 6 |
clinical efficacy | 6 |
enhance infection | 6 |
entry pathway | 6 |
potential targets | 6 |
associated coronavirus | 6 |
basic amino | 6 |
immunosorbent assays | 6 |
grand island | 6 |
infection status | 6 |
virus reduction | 6 |
diagnostic tests | 6 |
active form | 6 |
genus ebolavirus | 6 |
exporting countries | 6 |
antigen expression | 6 |
pig model | 6 |
completely protects | 6 |
ic value | 6 |
high case | 6 |
phylogenetic tree | 6 |
embryonic kidney | 6 |
bacteriophage phi | 6 |
phase clinical | 6 |
deleted ebov | 6 |
ucsf chimera | 6 |
hemorrhagic manifestations | 6 |
recombinant ad | 6 |
filovirus receptor | 6 |
virus outbreaks | 6 |
march blocks | 6 |
akt mtor | 6 |
fever outbreak | 6 |
mtor signaling | 6 |
outbreak scenarios | 6 |
virus variants | 6 |
interferon system | 6 |
virus assembly | 6 |
interim analysis | 6 |
protect guinea | 6 |
two independent | 6 |
multivariate analyses | 6 |
infection prevention | 6 |
previously identified | 6 |
vp inhibits | 6 |
image processing | 6 |
fda drugs | 6 |
fresh culture | 6 |
assay conditions | 6 |
hyperimmune sera | 6 |
viruses may | 6 |
relative importance | 6 |
research facility | 6 |
blot analysis | 6 |
filovirus species | 6 |
clomiphene blocks | 6 |
lectin specific | 6 |
ml rvsv | 6 |
genetic diversity | 6 |
average virus | 6 |
purified igg | 6 |
cytopathic effects | 6 |
systematic review | 6 |
virus vectors | 6 |
study showed | 6 |
mediated viral | 6 |
log pfu | 6 |
effective antiviral | 6 |
additional days | 6 |
analyzed using | 6 |
affinity chromatography | 6 |
rnp formation | 6 |
series word | 6 |
infected pigs | 6 |
also tested | 6 |
also contribute | 6 |
ring domain | 6 |
molecular characterization | 6 |
large outbreaks | 6 |
directed expression | 6 |
short stretch | 6 |
epitope conservancy | 6 |
different assays | 6 |
luminal domain | 6 |
approved selective | 6 |
extracellular vesicle | 6 |
worst case | 6 |
specific parameters | 6 |
pcr confirmed | 6 |
lethal experimental | 6 |
virus structure | 6 |
infected guinea | 6 |
key residues | 6 |
endemic countries | 6 |
total protein | 6 |
phi may | 6 |
convertase furin | 6 |
fusion form | 6 |
peptide sequence | 6 |
postexposure treatment | 6 |
pathogen reduction | 6 |
among patients | 6 |
healthcare life | 6 |
cell targeting | 6 |
ebov rt | 6 |
filovirus host | 6 |
serum levels | 6 |
entry factor | 6 |
risk analysis | 6 |
mediated isothermal | 6 |
per group | 6 |
protein data | 6 |
biological weapons | 6 |
animal care | 6 |
data bank | 6 |
pump inhibitors | 6 |
convalescent sera | 6 |
ifn antagonist | 6 |
biochemical analysis | 6 |
leone ebola | 6 |
pick disease | 6 |
highly lethal | 6 |
currently circulating | 6 |
proteases cathepsin | 6 |
conjugated goat | 6 |
person transmission | 6 |
serum dilution | 6 |
kidney cells | 6 |
relatively high | 6 |
conditions tested | 6 |
life sciences | 6 |
remains unclear | 6 |
ebov exposure | 6 |
antiviral drug | 6 |
potently neutralizing | 6 |
fold greater | 6 |
haemorrhagic fevers | 6 |
small nonhuman | 6 |
mononucleotide composition | 6 |
natural infection | 6 |
gabonese bat | 6 |
oxygen species | 6 |
survival rates | 6 |
arms races | 6 |
pseudotype viruses | 6 |
targeting gp | 6 |
mean time | 6 |
ebov variant | 6 |
leader panhandle | 6 |
least three | 6 |
outbreak strain | 6 |
protects guinea | 6 |
newly discovered | 6 |
endosomal pathway | 6 |
adenovirus vectors | 6 |
done using | 6 |
scientificreports www | 6 |
inducible gene | 6 |
human survivors | 6 |
strong inflammatory | 6 |
screening assay | 6 |
helical nucleocapsid | 6 |
disease outcome | 6 |
ph dependence | 6 |
recent report | 6 |
axl enhances | 6 |
productively infected | 6 |
lipid raft | 6 |
coronavirus disease | 6 |
infection via | 6 |
ns protein | 6 |
significantly lower | 6 |
mutational analysis | 6 |
sensor surface | 6 |
posttranslational modification | 6 |
inhibit hiv | 6 |
activated dcs | 6 |
protein interaction | 6 |
vp expression | 6 |
human npc | 6 |
integrated research | 6 |
bundibugyo virus | 6 |
rna silencing | 6 |
risk assessment | 6 |
human mpxv | 6 |
molecule entry | 6 |
mediated phosphorylation | 6 |
visible light | 6 |
available online | 6 |
tetherin bst | 6 |
stabilized matrix | 6 |
oligonucleotide composition | 6 |
phase trials | 6 |
verapamil inhibit | 6 |
mediate viral | 6 |
viruses causing | 6 |
highest probability | 6 |
another approach | 6 |
accidental exposure | 6 |
cocktail antibodies | 6 |
particle formation | 6 |
ebov igy | 6 |
human filovirus | 6 |
alexa fluor | 6 |
favorable interactions | 6 |
african fruit | 6 |
infected rhesus | 6 |
juvenile rousettus | 6 |
go scfv | 6 |
average weight | 6 |
second luminal | 6 |
mature dendritic | 6 |
kinome data | 6 |
reduce viral | 6 |
protective monotherapy | 6 |
vsv infection | 6 |
laboratory animal | 6 |
endogenous viral | 6 |
gp shedding | 6 |
computational analysis | 6 |
using two | 6 |
rna interactions | 6 |
immunized intramuscularly | 6 |
serum albumin | 6 |
breast cancer | 6 |
liver function | 6 |
particles containing | 6 |
immune mediators | 6 |
virus polymerases | 6 |
viral release | 6 |
novel therapeutic | 6 |
minigenome system | 6 |
strain mayinga | 6 |
vp blocks | 6 |
genomic analysis | 6 |
online version | 6 |
infected monocytes | 6 |
rinderpest virus | 6 |
matrix proteins | 6 |
breast milk | 6 |
nucleotide variations | 6 |
productive infection | 6 |
convalescent blood | 6 |
animal mortality | 6 |
diagnostic performance | 6 |
chronic hepatitis | 6 |
surface glycoproteins | 6 |
approved drug | 6 |
employ different | 6 |
disease symptoms | 6 |
like phenotype | 6 |
may lead | 6 |
new ebola | 6 |
pathogen inactivation | 6 |
relative humidity | 6 |
antibody titer | 5 |
rna polymerases | 5 |
shown previously | 5 |
novel broad | 5 |
based analyses | 5 |
genomic sequencing | 5 |
observational study | 5 |
luciferase activity | 5 |
interferon production | 5 |
broad spectrum | 5 |
diagnostic assays | 5 |
dc subsets | 5 |
vaccines protect | 5 |
purified equine | 5 |
protect nhps | 5 |
antiviral factor | 5 |
glycosylated gp | 5 |
sera collected | 5 |
cellular factors | 5 |
significance level | 5 |
ebola rna | 5 |
evolutionary history | 5 |
receptor activity | 5 |
buffered formalin | 5 |
hepatic lesions | 5 |
antibody fails | 5 |
efficient growth | 5 |
coding region | 5 |
transfection medium | 5 |
relatively short | 5 |
viruses replicate | 5 |
cytotoxic effects | 5 |
analogue bcx | 5 |
endosomal ph | 5 |
visit http | 5 |
santa cruz | 5 |
two major | 5 |
tmrca estimates | 5 |
ape populations | 5 |
nucleotide changes | 5 |
amphiphiles induce | 5 |
multiple ebola | 5 |
extensive intravascular | 5 |
human anti | 5 |
reverse transcriptase | 5 |
tetherin restriction | 5 |
highly glycosylated | 5 |
lung tissue | 5 |
sporadic outbreaks | 5 |
many viruses | 5 |
threshold values | 5 |
analysis using | 5 |
three mabs | 5 |
cell factors | 5 |
antigen presenting | 5 |
may influence | 5 |
hydrophobic interactions | 5 |
ebov dissemination | 5 |
asialoglycoprotein receptor | 5 |
reservoir host | 5 |
glycoprotein expressed | 5 |
test sera | 5 |
virus marburg | 5 |
ebov pathogenesis | 5 |
early treatment | 5 |
immune globulin | 5 |
underlying coagulation | 5 |
derived macrophages | 5 |
adenovirus vector | 5 |
cells might | 5 |
vlp injection | 5 |
greater fusion | 5 |
cells may | 5 |
pathogen recognition | 5 |
without inducing | 5 |
envelope proteins | 5 |
dna microarrays | 5 |
high yield | 5 |
epitope database | 5 |
solid substrates | 5 |
emerging diseases | 5 |
thermal stability | 5 |
neutralising activity | 5 |
pandemic potential | 5 |
sudv outbreak | 5 |
antiviral effectors | 5 |
gorilla fecal | 5 |
limited number | 5 |
viral infectivity | 5 |
block ebola | 5 |
antibody capture | 5 |
virus protein | 5 |
suspected evd | 5 |
derived monoclonal | 5 |
recent west | 5 |
kinase axl | 5 |
cover slips | 5 |
jac online | 5 |
pseudoparticles bearing | 5 |
old world | 5 |
human primate | 5 |
relatively small | 5 |
particles bearing | 5 |
ebov sample | 5 |
highly accurate | 5 |
virion incorporation | 5 |
four compounds | 5 |
clinical syndromes | 5 |
inhibits viral | 5 |
ddi technique | 5 |
wild apes | 5 |
arise independently | 5 |
unless otherwise | 5 |
drug development | 5 |
leader interaction | 5 |
stick injury | 5 |
significant inhibition | 5 |
ion channel | 5 |
indicated drug | 5 |
confidence interval | 5 |
key event | 5 |
different times | 5 |
san diego | 5 |
research institute | 5 |
one virus | 5 |
note springer | 5 |
linked glycosylation | 5 |
surface expression | 5 |
may contain | 5 |
relative ranking | 5 |
mediated cleavage | 5 |
preliminary data | 5 |
evd pathogenesis | 5 |
accessibility prediction | 5 |
promote fusion | 5 |
patient care | 5 |
human cytomegalovirus | 5 |
different time | 5 |
immune epitope | 5 |
particle image | 5 |
health issues | 5 |
dimethyl sulfoxide | 5 |
np oligomerization | 5 |
virus membrane | 5 |
interferon alpha | 5 |
growth medium | 5 |
candidate vaccine | 5 |
comparative analysis | 5 |
clinical care | 5 |
primarily via | 5 |
four hours | 5 |
randomly assigned | 5 |
pdb id | 5 |
viral sensing | 5 |
gp mediates | 5 |
viruses battle | 5 |
interfering rna | 5 |
phosphatidylserine receptors | 5 |
subunit vaccines | 5 |
northern blot | 5 |
contains supplementary | 5 |
agent disease | 5 |
tissue samples | 5 |
acceptable safety | 5 |
gp spikes | 5 |
assays used | 5 |
virus stocks | 5 |
beta interferon | 5 |
antiviral therapy | 5 |
loop structure | 5 |
ebola glycoproteins | 5 |
scientific reports | 5 |
tm domains | 5 |
sl ebov | 5 |
beta therapy | 5 |
well established | 5 |
washed three | 5 |
first step | 5 |
hydrophobic features | 5 |
recombinant antigen | 5 |
wag i | 5 |
potential vaccine | 5 |
fasman beta | 5 |
cells per | 5 |
protease inhibitors | 5 |
index case | 5 |
integrated density | 5 |
marv particles | 5 |
newly synthesized | 5 |
trvlp system | 5 |
core structure | 5 |
experimentally validated | 5 |
borne zoonotic | 5 |
fatal ebola | 5 |
secondary infections | 5 |
vectored vaccines | 5 |
thermo scientific | 5 |
four fda | 5 |
complete genome | 5 |
proton pump | 5 |
biological processes | 5 |
blood viral | 5 |
reduce ebov | 5 |
enhances macropinocytosis | 5 |
different steps | 5 |
shed active | 5 |
risk estimate | 5 |
mediated neutralization | 5 |
npc ortholog | 5 |
pcr assay | 5 |
class ii | 5 |
day course | 5 |
regression lines | 5 |
new cases | 5 |
high concentrations | 5 |
therapeutic oligonucleotides | 5 |
efficacy studies | 5 |
mva boost | 5 |
rvsv ebola | 5 |
fusion kinetics | 5 |
negative septicemia | 5 |
relative risk | 5 |
biological samples | 5 |
aerosol transmission | 5 |
convalescent ebola | 5 |
seven structural | 5 |
baseline model | 5 |
passage number | 5 |
lsectin interacts | 5 |
pv assays | 5 |
inflammatory mediators | 5 |
virus involves | 5 |
without vlp | 5 |
ebola gp | 5 |
based ebov | 5 |
several viruses | 5 |
largest outbreak | 5 |
mean hospitalization | 5 |
ongoing evd | 5 |
control serum | 5 |
concentrations used | 5 |
immune defense | 5 |
vp matrix | 5 |
will need | 5 |
viral growth | 5 |
secretory pathway | 5 |
antibody spots | 5 |
protein structures | 5 |
direct evidence | 5 |
later stages | 5 |
emini surface | 5 |
upregulates siglec | 5 |
virus survival | 5 |
intravascular apoptosis | 5 |
inhibitory domain | 5 |
additional file | 5 |
viral budding | 5 |
ebov zaire | 5 |
adenine analogues | 5 |
gp interaction | 5 |
days prior | 5 |
multiple comparison | 5 |
structure prediction | 5 |
linear epitope | 5 |
mouse antibody | 5 |
primate monocytes | 5 |
vsv expressing | 5 |
filoviral gps | 5 |
six animals | 5 |
promotes filovirus | 5 |
rate estimates | 5 |
atcc crl | 5 |
two years | 5 |
smaller form | 5 |
phi persisted | 5 |
persisted longer | 5 |
important factors | 5 |
washed times | 5 |
mathematical modeling | 5 |
sudan ebov | 5 |
studies indicate | 5 |
side chains | 5 |
suitable surrogate | 5 |
nipah viruses | 5 |
china friendship | 5 |
subunits gp | 5 |
fusion experiments | 5 |
nhps survived | 5 |
nuclear factor | 5 |
positive correlation | 5 |
induced disease | 5 |
ravn virus | 5 |
ebov trvlps | 5 |
test values | 5 |
antibody treatment | 5 |
filovirus pathogenesis | 5 |
per dose | 5 |
asymptomatic infection | 5 |
atcc ccl | 5 |
health emergency | 5 |
vlp preparations | 5 |
based pseudotyped | 5 |
immobilization step | 5 |
vp virus | 5 |
glycoproteins enhances | 5 |
high prevalence | 5 |
binding assays | 5 |
concept study | 5 |
elisa using | 5 |
glycoprotein counteracts | 5 |
viral nucleocapsid | 5 |
emerging viraly | 5 |
defective recombinant | 5 |
disease treatment | 5 |
ebov transduction | 5 |
may shed | 5 |
may indicate | 5 |
electronic supplementary | 5 |
tumor virus | 5 |
egg yolk | 5 |
arabian peninsula | 5 |
human respiratory | 5 |
may represent | 5 |
safety data | 5 |
case management | 5 |
virtual screening | 5 |
blood urea | 5 |
virus decay | 5 |
conserved among | 5 |
naturally infected | 5 |
reporter vlps | 5 |
receptor npc | 5 |
footprint similarity | 5 |
safety concerns | 5 |
binding buffer | 5 |
gene assay | 5 |
fever associated | 5 |
rapid detection | 5 |
final volume | 5 |
ebov itu | 5 |
female mice | 5 |
hamster model | 5 |
authorized users | 5 |
tmprss expression | 5 |
type mice | 5 |
comprehensive analysis | 5 |
absorbent pad | 5 |
natural killer | 5 |
randomized trials | 5 |
collected blood | 5 |
inactivated ebov | 5 |
stainless steel | 5 |
vp structure | 5 |
complementary dna | 5 |
liver pathology | 5 |
experiments performed | 5 |
work suggests | 5 |
persistent ebov | 5 |
feature pharmacophore | 5 |
survival time | 5 |
disease epidemic | 5 |
virus amplification | 5 |
particle vaccine | 5 |
mobile laboratory | 5 |
serum proteins | 5 |
evd vaccine | 5 |
offered protection | 5 |
host adaptation | 5 |
newcastle disease | 5 |
different viral | 5 |
virus dissemination | 5 |
household contacts | 5 |
ccd camera | 5 |
test serum | 5 |
background level | 5 |
propensity score | 5 |
compassionate use | 5 |
linear regression | 5 |
using artificial | 5 |
may include | 5 |
proteins inhibit | 5 |
highly effective | 5 |
elapsed months | 5 |
effective treatment | 5 |
filovirus budding | 5 |
future work | 5 |
unpublished essential | 5 |
marv ci | 5 |
ebov via | 5 |
three species | 5 |
vp impairs | 5 |
geographic areas | 5 |